Jefferies initiated coverage on NeoGenomics with a new price target
$NEO
Precision Instruments
Health Care
Jefferies initiated coverage of NeoGenomics with a rating of Buy and set a new price target of $22.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2025 | Buy → Hold | The Benchmark Company | |
| 12/10/2024 | $22.00 | Buy | Jefferies |
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 5/9/2023 | $25.00 | Neutral → Buy | BTIG Research |
| 2/24/2023 | $20.00 | Hold → Buy | The Benchmark Company |
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o
Patients and physicians will benefit from access to NeoGenomics' broad test menu and high-quality laboratory services in the Tri-state area NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing. About
NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company's Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in healthcare. "Tony has a strong command of the healthcare landscape and a deep understanding of the opportunities ahead for NeoGenomics," said Lynn Tetrault, Chair of the Board. "His experience leading commercial and operational teams, combined with his significant connection to our strategy, make him the
The Benchmark Company downgraded NeoGenomics from Buy to Hold
Jefferies initiated coverage of NeoGenomics with a rating of Buy and set a new price target of $22.00
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
DEF 14A - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
8-K/A - NEOGENOMICS INC (0001077183) (Filer)
Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o
NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev
Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter consolidated revenue increased 11% to $172 million; Full year consolidated revenue increased 12% to $661 million Fourth quarter net loss increased 7% to $15 million; Full year net loss decreased 11% to $79 million Fourth quarter adjusted EBITDA increased 27% to positive $12 million; Full year adjusted EBITDA increased 1,036% to
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)